LONDON – The European Commission offered up to €80 million (US$89.4 million) of funding to Curevac AG, to scale up development and production of a vaccine against the coronavirus in Europe, following reports that the U.S. administration had made an offer for the German biotech, in order to get exclusive control of its COVID-19 vaccine candidate.
Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Advanz, Akebia, Amarin, Armas, Brainstorm, Correvio, Homology, Kirin, Medivir, Nanoviricides, Pharmamar, Protalix, Spherix, Tango, Tetraphase, Therapeuticsmd, Twist, Xortx.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AGTC, Aimmune, Aptevo, Arcutis, Biocryst, Can-Fite, Genetx, Moderna, Novo Nordisk, Regeneron, Sanofi.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bausch Health, Bioreference Laboratories, Cherrycircle Software, Co-Diagnostics, Evisit, Luminex, Medable, MIP Diagnostics, National Kidney Foundation, Opko, Precheck Health Services, Qiagen, Science37, Veravas, Vitalhub.
Mallinckrodt plc is engaging with the U.S. FDA, NIH and the Biomedical Advanced Research and Development Authority to address the potential use of its INOmax (nitric oxide) inhaled gas to treat COVID-19-associated lung complications. INOmax is marketed in the U.S. by the Staines-upon-Thames, U.K.-based company to treat full- and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.